Open AccessIntravitreal aflibercept treatment for choroidal neovascularization secondary to laser pointer
Author(s) -
Ali Keleş,
Suleyman Korhan Karaman
Publication year - 2020
Publication title -
oman journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.306
H-Index - 16
eISSN - 0974-7842
pISSN - 0974-620X
DOI - 10.4103/ojo.ojo_10_2019
Subject(s) - medicine , choroidal neovascularization , aflibercept , laser pointer , ophthalmology , optical coherence tomography , fundus (uterus) , fluorescein angiography , visual acuity , foveal , bevacizumab , laser , surgery , optics , retinal , chemotherapy , physics
A 15-year-old male was presented with blurred vision in his right eye for 2 weeks. The patient had a history of looking with the right eye for 5-6 s at a distance of 20 cm from green laser beam (class 3a, 5 mW, 532 nm). Dilated fundus examinations revealed a yellow lesion in the right eye, resulting in loss of foveal reflection at the fovea. Fundus fluorescein angiography (FFA) images and spectral-domain optical coherence tomography (OCT) scans were compatible with active classic choroidal neovascularization (CNV). A single dose of intravitreal aflibercept was performed to the right eye, and at the 1st month after the injection, the best-corrected visual acuity improved to 20/100 from 20/200. FFA showed staining of the scar with no leakage, and OCT revealed scar formation. At the follow-up visits, during 38-month follow-up, no CNV activity was observed. Intravitreal aflibercept may be an appropriate treatment option in cases with laser pointer injury-induced CNV.